Stryker to Buy Entellus Medical For $662 Million
07 Dezembro 2017 - 12:15PM
Dow Jones News
By Austen Hufford
Stryker Corp. (SYK) is buying Entellus Medical Inc. (ENTL) for
about $662 million, or $24 a share.
Entellus makes products for the minimally invasive treatment of
chronic and recurrent sinusitis, a condition where sinuses become
infected. The deal's value is a 49% premium over the company's
closing price Wednesday.
Entellus was founded in 2006 and is headquartered in Plymouth,
Minn.
Stryker said the business is complementary to the existing ear,
nose, and throat portfolio of its instruments business.
The transaction is expected to dent Stryker's 2018 adjusted net
earnings per share by about 4 cents and then add to per-share
earnings afterward.
Entellus had revenue of $75.2 million in 2016 and reported a net
loss of $28.7 million.
Write to Austen Hufford at Austen.Hufford@wsj.com
(END) Dow Jones Newswires
December 07, 2017 09:00 ET (14:00 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
ENTELLUS MEDICAL INC (NASDAQ:ENTL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ENTELLUS MEDICAL INC (NASDAQ:ENTL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Entellus Medical, Inc. (delisted) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Entellus Medical, Inc. (MM)